Do analysts prefer RKDA or KO?

CocaCola has a consensus target price of $95.76, suggesting a potential upside of 8.42%. Given CocaCola's stronger consensus rating and higher possible upside, analysts clearly believe CocaCola is more favorable than Arcadia Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcadia Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CocaCola 0 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.89

Do analysts recommend PEP or RKDA?

PepsiCo presently has a consensus target price of $157.90, suggesting a potential upside of 15.83%. Given PepsiCo's stronger consensus rating and higher probable upside, equities research analysts clearly believe PepsiCo is more favorable than Arcadia Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepsiCo 1 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.30 Arcadia Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PEP or RKDA more profitable?

PepsiCo has a net margin of 10.78% compared to Arcadia Biosciences' net margin of -234.53%. PepsiCo's return on equity of 54.63% beat Arcadia Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets PepsiCo 10.78% 54.63% 10.49% Arcadia Biosciences -234.53% -183.50% -91.25%

Do analysts prefer KOF or RKDA?

Coca Cola Femsa currently has a consensus target price of $118.83, suggesting a potential upside of 7.55%. Given Coca Cola Femsa's stronger consensus rating and higher possible upside, equities research analysts clearly believe Coca Cola Femsa is more favorable than Arcadia Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coca Cola Femsa 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Arcadia Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate RKDA or MNST?

Monster Beverage has a consensus target price of $50.33, suggesting a potential upside of 15.96%. Given Monster Beverage's stronger consensus rating and higher probable upside, analysts plainly believe Monster Beverage is more favorable than Arcadia Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcadia Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Monster Beverage 0 Sell rating(s) 9 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.59

Do analysts recommend RKDA or CCEP?

Coca-Cola Europacific Partners has a consensus target price of $108.44, indicating a potential upside of 5.52%. Given Coca-Cola Europacific Partners' stronger consensus rating and higher probable upside, analysts plainly believe Coca-Cola Europacific Partners is more favorable than Arcadia Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcadia Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Coca-Cola Europacific Partners 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55

Which has stronger valuation & earnings, RKDA or CCEP?

Coca-Cola Europacific Partners has higher revenue and earnings than Arcadia Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcadia Biosciences $4.86M 0.21 -$2.34M -$4.56 N/A Coca-Cola Europacific Partners $23.64B 2.00 $2.20B N/A N/A

Arcadia Biosciences (RKDA) Competitors

$0.43 -0.02 (-4.81%)

As of 09/11/2026 03:49 PM Eastern

Compare

RKDA vs. KO, PEP, KOF, MNST, and CCEP

Should you buy Arcadia Biosciences stock or one of its competitors? Arcadia Biosciences's main competitors and comparable companies include CocaCola (KO), PepsiCo (PEP), Coca Cola Femsa (KOF), Monster Beverage (MNST), and Coca-Cola Europacific Partners (CCEP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "soft drinks & non-alcoholic beverages" industry.

How does Arcadia Biosciences compare to CocaCola?

Arcadia Biosciences (NASDAQ:RKDA) and CocaCola (NYSE:KO) are both consumer staples companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

CocaCola has a net margin of 28.56% compared to Arcadia Biosciences' net margin of -234.53%. CocaCola's return on equity of 39.38% beat Arcadia Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcadia Biosciences	-234.53%	-183.50%	-91.25%
CocaCola	28.56%	39.38%	13.18%

In the previous week, CocaCola had 52 more articles in the media than Arcadia Biosciences. MarketBeat recorded 54 mentions for CocaCola and 2 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.43 beat CocaCola's score of 0.93 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Arcadia Biosciences	Positive
CocaCola	Positive

Arcadia Biosciences has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, CocaCola has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

CocaCola has a consensus target price of $95.76, suggesting a potential upside of 8.42%. Given CocaCola's stronger consensus rating and higher possible upside, analysts clearly believe CocaCola is more favorable than Arcadia Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcadia Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CocaCola	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 70.3% of CocaCola shares are owned by institutional investors. 4.5% of Arcadia Biosciences shares are owned by insiders. Comparatively, 0.9% of CocaCola shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CocaCola has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than CocaCola, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcadia Biosciences	$4.86M	0.21	-$2.34M	-$4.56	N/A
CocaCola	$47.94B	7.93	$13.11B	$3.33	26.52

Summary

CocaCola beats Arcadia Biosciences on 14 of the 17 factors compared between the two stocks.

How does Arcadia Biosciences compare to PepsiCo?

PepsiCo (NASDAQ:PEP) and Arcadia Biosciences (NASDAQ:RKDA) are both consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

PepsiCo has a net margin of 10.78% compared to Arcadia Biosciences' net margin of -234.53%. PepsiCo's return on equity of 54.63% beat Arcadia Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepsiCo	10.78%	54.63%	10.49%
Arcadia Biosciences	-234.53%	-183.50%	-91.25%

In the previous week, PepsiCo had 41 more articles in the media than Arcadia Biosciences. MarketBeat recorded 43 mentions for PepsiCo and 2 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.43 beat PepsiCo's score of 0.85 indicating that Arcadia Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
PepsiCo	Positive
Arcadia Biosciences	Positive

PepsiCo has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

PepsiCo presently has a consensus target price of $157.90, suggesting a potential upside of 15.83%. Given PepsiCo's stronger consensus rating and higher probable upside, equities research analysts clearly believe PepsiCo is more favorable than Arcadia Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepsiCo	1 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.30
Arcadia Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PepsiCo has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than PepsiCo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepsiCo	$93.93B	1.98	$8.24B	$7.63	17.87
Arcadia Biosciences	$4.86M	0.21	-$2.34M	-$4.56	N/A

73.1% of PepsiCo shares are held by institutional investors. Comparatively, 17.7% of Arcadia Biosciences shares are held by institutional investors. 0.1% of PepsiCo shares are held by company insiders. Comparatively, 4.5% of Arcadia Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

PepsiCo beats Arcadia Biosciences on 13 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Coca Cola Femsa?

Coca Cola Femsa (NYSE:KOF) and Arcadia Biosciences (NASDAQ:RKDA) are both consumer staples companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Coca Cola Femsa has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

17.7% of Arcadia Biosciences shares are owned by institutional investors. 1.0% of Coca Cola Femsa shares are owned by company insiders. Comparatively, 4.5% of Arcadia Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Coca Cola Femsa currently has a consensus target price of $118.83, suggesting a potential upside of 7.55%. Given Coca Cola Femsa's stronger consensus rating and higher possible upside, equities research analysts clearly believe Coca Cola Femsa is more favorable than Arcadia Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coca Cola Femsa	0 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.44
Arcadia Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coca Cola Femsa has a net margin of 8.05% compared to Arcadia Biosciences' net margin of -234.53%. Coca Cola Femsa's return on equity of 15.83% beat Arcadia Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coca Cola Femsa	8.05%	15.83%	7.32%
Arcadia Biosciences	-234.53%	-183.50%	-91.25%

In the previous week, Coca Cola Femsa had 1 more articles in the media than Arcadia Biosciences. MarketBeat recorded 3 mentions for Coca Cola Femsa and 2 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.43 beat Coca Cola Femsa's score of 0.65 indicating that Arcadia Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Coca Cola Femsa	Positive
Arcadia Biosciences	Positive

Coca Cola Femsa has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Coca Cola Femsa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coca Cola Femsa	$15.22B	12.20	$1.32B	$6.34	17.43
Arcadia Biosciences	$4.86M	0.21	-$2.34M	-$4.56	N/A

Summary

Coca Cola Femsa beats Arcadia Biosciences on 12 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Monster Beverage?

Arcadia Biosciences (NASDAQ:RKDA) and Monster Beverage (NASDAQ:MNST) are both consumer staples companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Monster Beverage has higher revenue and earnings than Arcadia Biosciences. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Monster Beverage, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcadia Biosciences	$4.86M	0.21	-$2.34M	-$4.56	N/A
Monster Beverage	$9.22B	9.22	$1.91B	$1.08	40.19

Monster Beverage has a net margin of 23.08% compared to Arcadia Biosciences' net margin of -234.53%. Monster Beverage's return on equity of 26.02% beat Arcadia Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcadia Biosciences	-234.53%	-183.50%	-91.25%
Monster Beverage	23.08%	26.02%	21.21%

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 72.4% of Monster Beverage shares are held by institutional investors. 4.5% of Arcadia Biosciences shares are held by company insiders. Comparatively, 8.1% of Monster Beverage shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Monster Beverage has a consensus target price of $50.33, suggesting a potential upside of 15.96%. Given Monster Beverage's stronger consensus rating and higher probable upside, analysts plainly believe Monster Beverage is more favorable than Arcadia Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcadia Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Monster Beverage	0 Sell rating(s)	9 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.59

Arcadia Biosciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Monster Beverage has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

In the previous week, Monster Beverage had 7 more articles in the media than Arcadia Biosciences. MarketBeat recorded 9 mentions for Monster Beverage and 2 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.43 beat Monster Beverage's score of 0.56 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Arcadia Biosciences	Positive
Monster Beverage	Positive

Summary

Monster Beverage beats Arcadia Biosciences on 14 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Coca-Cola Europacific Partners?

Arcadia Biosciences (NASDAQ:RKDA) and Coca-Cola Europacific Partners (NASDAQ:CCEP) are both consumer staples companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Coca-Cola Europacific Partners has higher revenue and earnings than Arcadia Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcadia Biosciences	$4.86M	0.21	-$2.34M	-$4.56	N/A
Coca-Cola Europacific Partners	$23.64B	2.00	$2.20B	N/A	N/A

In the previous week, Coca-Cola Europacific Partners had 5 more articles in the media than Arcadia Biosciences. MarketBeat recorded 7 mentions for Coca-Cola Europacific Partners and 2 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.43 beat Coca-Cola Europacific Partners' score of 1.13 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Arcadia Biosciences	Positive
Coca-Cola Europacific Partners	Positive

Coca-Cola Europacific Partners has a consensus target price of $108.44, indicating a potential upside of 5.52%. Given Coca-Cola Europacific Partners' stronger consensus rating and higher probable upside, analysts plainly believe Coca-Cola Europacific Partners is more favorable than Arcadia Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcadia Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Coca-Cola Europacific Partners	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Coca-Cola Europacific Partners has a net margin of 0.00% compared to Arcadia Biosciences' net margin of -234.53%. Coca-Cola Europacific Partners' return on equity of 0.00% beat Arcadia Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcadia Biosciences	-234.53%	-183.50%	-91.25%
Coca-Cola Europacific Partners	N/A	N/A	N/A

Arcadia Biosciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Coca-Cola Europacific Partners has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 31.4% of Coca-Cola Europacific Partners shares are owned by institutional investors. 4.5% of Arcadia Biosciences shares are owned by insiders. Comparatively, 3.0% of Coca-Cola Europacific Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Coca-Cola Europacific Partners beats Arcadia Biosciences on 11 of the 14 factors compared between the two stocks.

Get Arcadia Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RKDA vs. The Competition

Export

Metric	Arcadia Biosciences	Beverages Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$1.04M	$22.36B	$15.57B	$12.85B
Dividend Yield	N/A	2.71%	3.27%	11.17%
P/E Ratio	-0.09	16.79	14.06	25.36
Price / Sales	0.21	29.63	262,948.62	116.82
Price / Cash	0.33	17.47	56.87	51.52
Price / Book	0.18	3.86	4.76	6.20
Net Income	-$2.34M	$906.50M	$837.55M	$358.50M
7 Day Performance	-8.78%	-1.72%	-1.42%	-2.35%
1 Month Performance	-24.36%	-1.80%	-1.79%	-3.23%
1 Year Performance	-87.34%	-8.41%	10.48%	8.79%

Arcadia Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RKDA Arcadia Biosciences	1.4007 of 5 stars	$0.43 -4.8%	N/A	-87.3%	$1.04M	$4.86M	N/A	60	Short Interest Decrease
KO CocaCola	4.4875 of 5 stars	$87.53 -0.9%	$95.76 +9.4%	+31.8%	$376.59B	$50.13B	26.28	65,900	Trending News Analyst Revision
PEP PepsiCo	4.7193 of 5 stars	$136.69 -1.3%	$157.90 +15.5%	-5.0%	$186.57B	$93.93B	17.91	306,000	Trending News
KOF Coca Cola Femsa	4.084 of 5 stars	$109.36 -0.2%	$118.83 +8.7%	+28.8%	$183.80B	$296.20B	17.25	108,925	News Coverage Analyst Downgrade
MNST Monster Beverage	3.2332 of 5 stars	$42.84 -0.7%	$50.33 +17.5%	+34.2%	$83.93B	$8.29B	39.67	6,891	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RKDA) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcadia Biosciences (RKDA) Competitors

RKDA vs. KO, PEP, KOF, MNST, and CCEP

How does Arcadia Biosciences compare to CocaCola?

Summary

How does Arcadia Biosciences compare to PepsiCo?

Summary

How does Arcadia Biosciences compare to Coca Cola Femsa?

Summary

How does Arcadia Biosciences compare to Monster Beverage?

Summary

How does Arcadia Biosciences compare to Coca-Cola Europacific Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKDA vs. The Competition

Arcadia Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcadia Biosciences (RKDA) Competitors

RKDA vs. KO, PEP, KOF, MNST, and CCEP

How does Arcadia Biosciences compare to CocaCola?

Is RKDA or KO more profitable?

Does the media favor RKDA or KO?

Which has more risk & volatility, RKDA or KO?

Do analysts prefer RKDA or KO?

Do insiders and institutionals hold more shares of RKDA or KO?

Which has stronger valuation and earnings, RKDA or KO?

Summary

How does Arcadia Biosciences compare to PepsiCo?

Is PEP or RKDA more profitable?

Does the media refer more to PEP or RKDA?

Which has more risk & volatility, PEP or RKDA?

Do analysts recommend PEP or RKDA?

Which has preferable earnings & valuation, PEP or RKDA?

Do institutionals and insiders hold more shares of PEP or RKDA?

Summary

How does Arcadia Biosciences compare to Coca Cola Femsa?

Which has more risk & volatility, KOF or RKDA?

Do institutionals & insiders hold more shares of KOF or RKDA?

Do analysts prefer KOF or RKDA?

Is KOF or RKDA more profitable?

Does the media refer more to KOF or RKDA?

Which has preferable valuation and earnings, KOF or RKDA?

Summary

How does Arcadia Biosciences compare to Monster Beverage?

Which has higher earnings and valuation, RKDA or MNST?

Is RKDA or MNST more profitable?

Do insiders & institutionals hold more shares of RKDA or MNST?

Do analysts rate RKDA or MNST?

Which has more risk & volatility, RKDA or MNST?

Does the media prefer RKDA or MNST?

Summary

How does Arcadia Biosciences compare to Coca-Cola Europacific Partners?

Which has stronger valuation & earnings, RKDA or CCEP?

Does the media prefer RKDA or CCEP?

Do analysts recommend RKDA or CCEP?

Is RKDA or CCEP more profitable?

Which has more risk and volatility, RKDA or CCEP?

Do institutionals & insiders have more ownership in RKDA or CCEP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKDA vs. The Competition

Arcadia Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools